JP2019519489A5 - - Google Patents

Download PDF

Info

Publication number
JP2019519489A5
JP2019519489A5 JP2018558275A JP2018558275A JP2019519489A5 JP 2019519489 A5 JP2019519489 A5 JP 2019519489A5 JP 2018558275 A JP2018558275 A JP 2018558275A JP 2018558275 A JP2018558275 A JP 2018558275A JP 2019519489 A5 JP2019519489 A5 JP 2019519489A5
Authority
JP
Japan
Prior art keywords
dry powder
particles
dry
powder inhalation
inhalation composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018558275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519489A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/031301 external-priority patent/WO2017192993A1/en
Publication of JP2019519489A publication Critical patent/JP2019519489A/ja
Publication of JP2019519489A5 publication Critical patent/JP2019519489A5/ja
Priority to JP2023031081A priority Critical patent/JP2023071844A/ja
Priority to JP2025077118A priority patent/JP2025118785A/ja
Pending legal-status Critical Current

Links

JP2018558275A 2016-05-05 2017-05-05 肺高血圧症を治療するための乾燥粉末トレプロスチニル Pending JP2019519489A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023031081A JP2023071844A (ja) 2016-05-05 2023-03-01 肺高血圧症を治療するための乾燥粉末トレプロスチニル
JP2025077118A JP2025118785A (ja) 2016-05-05 2025-05-07 肺高血圧症を治療するための乾燥粉末トレプロスチニル

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662332013P 2016-05-05 2016-05-05
US62/332,013 2016-05-05
US201662404960P 2016-10-06 2016-10-06
US62/404,960 2016-10-06
US201662440078P 2016-12-29 2016-12-29
US62/440,078 2016-12-29
US201762472204P 2017-03-16 2017-03-16
US62/472,204 2017-03-16
PCT/US2017/031301 WO2017192993A1 (en) 2016-05-05 2017-05-05 Dry powder treprostinil for the treatment of pulmonary hypertension

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023031081A Division JP2023071844A (ja) 2016-05-05 2023-03-01 肺高血圧症を治療するための乾燥粉末トレプロスチニル

Publications (2)

Publication Number Publication Date
JP2019519489A JP2019519489A (ja) 2019-07-11
JP2019519489A5 true JP2019519489A5 (cg-RX-API-DMAC7.html) 2020-06-18

Family

ID=60203775

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018558275A Pending JP2019519489A (ja) 2016-05-05 2017-05-05 肺高血圧症を治療するための乾燥粉末トレプロスチニル
JP2023031081A Pending JP2023071844A (ja) 2016-05-05 2023-03-01 肺高血圧症を治療するための乾燥粉末トレプロスチニル
JP2025077118A Pending JP2025118785A (ja) 2016-05-05 2025-05-07 肺高血圧症を治療するための乾燥粉末トレプロスチニル

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023031081A Pending JP2023071844A (ja) 2016-05-05 2023-03-01 肺高血圧症を治療するための乾燥粉末トレプロスチニル
JP2025077118A Pending JP2025118785A (ja) 2016-05-05 2025-05-07 肺高血圧症を治療するための乾燥粉末トレプロスチニル

Country Status (7)

Country Link
US (9) US10898494B2 (cg-RX-API-DMAC7.html)
EP (1) EP3452170A4 (cg-RX-API-DMAC7.html)
JP (3) JP2019519489A (cg-RX-API-DMAC7.html)
AU (3) AU2017261317A1 (cg-RX-API-DMAC7.html)
CA (1) CA3023257A1 (cg-RX-API-DMAC7.html)
IL (3) IL319790A (cg-RX-API-DMAC7.html)
WO (1) WO2017192993A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010259943C1 (en) 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
EP2861296A1 (en) * 2012-06-15 2015-04-22 Case Western Reserve University Therapy delivery devices and methods for non-damaging neural tissue conduction block
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
US9469600B2 (en) 2013-10-25 2016-10-18 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
US10343979B2 (en) 2014-11-18 2019-07-09 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US20190321290A1 (en) * 2016-01-29 2019-10-24 Mannkind Corporation Composition and method for inhalation
EP3452170A4 (en) 2016-05-05 2020-04-01 Liquidia Technologies, Inc. TREPROSTINIL IN POWDER FORM FOR TREATING PULMONAL HYPERTENSION
SG11202011045VA (en) * 2018-05-07 2020-12-30 Pharmosa Biopharm Inc Pharmaceutical composition for controlled release of treprostinil
CA3102967A1 (en) * 2018-06-07 2019-12-12 Mannkind Corporation Composition and method for inhalation
CN119632930A (zh) 2019-04-29 2025-03-18 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
CN114401716A (zh) 2019-07-22 2022-04-26 纳诺米有限公司 持续释放的曲前列环素-化合物微粒组合物
IL296567A (en) 2020-04-17 2022-11-01 United Therapeutics Corp Terfostinil for use in the treatment of interstitial lung disease
CN116437906B (zh) * 2020-10-28 2026-07-03 英斯梅德股份有限公司 曲前列环素前药的干粉组合物和其使用方法
CA3235985A1 (en) * 2021-10-27 2023-05-04 Mannkind Corporation Methods and compositions for treating pulmonary hypertension
WO2023154705A1 (en) * 2022-02-08 2023-08-17 United Therapeutics Corporation Treprostinil iloprost combination therapy
EP4516297A4 (en) 2022-04-29 2026-02-25 Zhaoke pharmaceutical guangzhou co ltd Treprostinil Gentle Inhalation Mist
WO2025174856A1 (en) * 2024-02-12 2025-08-21 Mannkind Corporation Process for making a composition for pulmonary inhalation

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56122328A (en) 1980-02-29 1981-09-25 Sumitomo Chem Co Ltd Crystalline amine salt of methanoplastocyclin, its preparation and purifying method
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
GB8814438D0 (en) 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
US5441060A (en) * 1993-02-08 1995-08-15 Duke University Dry powder delivery system
CH687615A5 (de) * 1994-09-07 1997-01-15 R W Johnson Pharmaceutical Res Tropen-Verpackung.
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US20030118567A1 (en) 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
US6521212B1 (en) * 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US7305986B1 (en) * 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
US6242482B1 (en) 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US6889690B2 (en) * 2002-05-10 2005-05-10 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
CN102697790A (zh) 2003-05-22 2012-10-03 联合治疗公司 化合物和释放前列环素类似物的方法
AU2004249166B2 (en) 2003-06-13 2008-10-09 Alkermes, Inc. Low dose pharmaceutical powders for inhalation
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
ATE551383T1 (de) 2003-09-23 2012-04-15 Univ North Carolina Photohärtbare perfluorpolyether zur verwendung als neue werkstoffe in mikrofluidischen vorrichtungen
US7199157B2 (en) 2003-12-16 2007-04-03 United Therapeutics Corporation Use of treprostinil to improve kidney functions
CN1917866B (zh) 2003-12-16 2010-12-15 联合治疗公司 曲前列环素或它的衍生物,或其药学上可接受的盐在制备治疗和预防缺血性损害的药物中的用途
WO2005101466A2 (en) 2003-12-19 2005-10-27 The University Of North Carolina At Chapel Hill Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography
US9214590B2 (en) 2003-12-19 2015-12-15 The University Of North Carolina At Chapel Hill High fidelity nano-structures and arrays for photovoltaics and methods of making the same
WO2007021762A2 (en) 2005-08-09 2007-02-22 The University Of North Carolina At Chapel Hill Methods and materials for fabricating microfluidic devices
DE602005020269D1 (de) 2004-04-12 2010-05-12 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
CA2574958A1 (en) 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
WO2007133808A2 (en) 2006-05-15 2007-11-22 Liquidia Technologies, Inc. Nano-particles for cosmetic applications
CA2654492C (en) 2006-05-15 2017-06-27 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
CA2655477C (en) 2006-06-16 2015-05-05 Cipla Limited Vibration assisted release of encapsulated inhalable powder
US20090036465A1 (en) 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
US8128393B2 (en) 2006-12-04 2012-03-06 Liquidia Technologies, Inc. Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom
WO2009049299A1 (en) 2007-10-12 2009-04-16 Liquidia Technologies, Inc. System and method for producing particles and patterned films
WO2009078965A1 (en) 2007-12-17 2009-06-25 United Therapeutics Corporation An improved process to prepare treprostinil, the active ingredient in remodulin
US20110151015A1 (en) 2008-03-04 2011-06-23 Liquikia Technologies, Inc. Immunomodulator particles and methods of treating
EP2257326A2 (en) * 2008-03-21 2010-12-08 Novartis AG Powder dispersion apparatus
JP6219016B2 (ja) 2008-05-08 2017-10-25 ユナイテッド セラピューティクス コーポレーション トレプロスチニル一水和物
WO2009150136A1 (de) 2008-06-09 2009-12-17 Boehringer Ingelheim International Gmbh Neue einbettungspartikel für die inhalation
WO2009152160A1 (en) * 2008-06-10 2009-12-17 Gilead Sciences, Inc. Inhaled carbaprostacyclin and prostacyclin prodrugs for the treatment of pulmonary arterial hypertension
EP2330893A4 (en) 2008-09-25 2013-01-09 Aradigm Corp DEEP PULMONARY ADMINISTRATION OF TREPROSTINIL
CN104162947B (zh) 2008-12-05 2017-04-12 流体科技公司 产生有图案的材料的方法
AU2010259943C1 (en) 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US20120114554A1 (en) 2009-07-13 2012-05-10 Liquidia Technologies, Inc. Engineered Aerosol Particles, And Associated Methods
AU2010280684B2 (en) 2009-08-07 2016-07-28 Scipharm Sarl Composition for the treatment of cystic fibrosis
EP2338520A1 (de) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung
US20130209564A1 (en) 2010-02-22 2013-08-15 Shyam M. Rele Polysaccharide Particle Vaccines
CN102869402A (zh) * 2010-04-23 2013-01-09 3M创新有限公司 干粉吸入器组件和容器
CA2726599C (en) 2010-12-30 2017-07-25 Alphora Research Inc. Process for treprostinil salt preparation
PL2663313T3 (pl) 2011-01-13 2019-01-31 SciPharm S.à r.l. Sposób zwiększania wszczepiania hematopoetycznych komórek macierzystych
JP5780775B2 (ja) 2011-02-18 2015-09-16 株式会社Lttバイオファーマ プロスタグランジンi2誘導体を含有するナノ粒子
EP2526926A1 (de) 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biokompatible Nanopolymerpartikel mit Wirkstoffen für die pulmonale Applikation
AU2012296953B2 (en) 2011-08-12 2016-10-20 Ascendis Pharma A/S Sustained release composition of prostacyclin
CA2850484C (en) 2011-09-30 2021-01-26 Bluebird Bio, Inc. Compounds for improved viral transduction
AU2012328524B2 (en) * 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
US9554968B2 (en) 2013-03-11 2017-01-31 Sio2 Medical Products, Inc. Trilayer coated pharmaceutical packaging
CN107875127A (zh) 2012-02-28 2018-04-06 艾塞尤提卡控股公司 可吸入药物组合物
US20150136130A1 (en) * 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
US10071209B2 (en) 2012-03-15 2018-09-11 Steadymed Ltd. Enhanced infusion-site pain-reduction for drug-delivery devices
CN104684561A (zh) 2012-08-01 2015-06-03 联合治疗公司 利用间充质干细胞的肺动脉高血压的治疗
WO2014085813A1 (en) 2012-11-30 2014-06-05 Insmed Incorporated Prostacylin compositions and methods for using the same
US9505737B2 (en) * 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
WO2014159050A1 (en) 2013-03-14 2014-10-02 United Therapeutics Corporation Solid forms of treprostinil
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
ITMI20130572A1 (it) * 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
CA2911172C (en) 2013-04-30 2021-10-19 United Therapeutics Corporation Controlled release pharmaceutical formulations
US9349730B2 (en) 2013-07-18 2016-05-24 Globalfoundries Inc. Fin transformation process and isolation structures facilitating different Fin isolation schemes
BR122019026637B1 (pt) * 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
ES2959419T3 (es) * 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
US9469600B2 (en) 2013-10-25 2016-10-18 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
GB201400412D0 (en) * 2014-01-10 2014-02-26 Heart Biotech Ltd Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
MX2016010213A (es) 2014-02-07 2017-04-13 Auspex Pharmaceuticals Inc Formulaciones farmaceuticas novedosas.
WO2015138423A1 (en) * 2014-03-11 2015-09-17 Insmed Incorporated Prostacylin compositions and methods for using the same
CA2963085C (en) * 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
IL260823B2 (en) 2016-01-29 2024-08-01 Mannkind Corp Dry powder inhaler
US20190321290A1 (en) 2016-01-29 2019-10-24 Mannkind Corporation Composition and method for inhalation
EP3452170A4 (en) 2016-05-05 2020-04-01 Liquidia Technologies, Inc. TREPROSTINIL IN POWDER FORM FOR TREATING PULMONAL HYPERTENSION
EP3554507A1 (en) 2016-12-14 2019-10-23 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
CA3102967A1 (en) 2018-06-07 2019-12-12 Mannkind Corporation Composition and method for inhalation
CN112739679B (zh) 2018-09-18 2024-03-12 伊莱利利公司 曲前列环素的特丁胺盐
JP7365073B2 (ja) 2019-05-21 2023-10-19 ジァンスー フォアフロント ファーマシューティカル カンパニー,リミテッド トレプロスチニルナトリウムの新規な結晶形および製造方法
CN114401716A (zh) 2019-07-22 2022-04-26 纳诺米有限公司 持续释放的曲前列环素-化合物微粒组合物

Similar Documents

Publication Publication Date Title
JP2018519818A5 (cg-RX-API-DMAC7.html)
ES2424476T3 (es) Nanopartículas cargadas con fármaco antitumoral quimioterápico
US20080066739A1 (en) Methods and systems of delivering medication via inhalation
RU2018113460A (ru) Вдыхаемые никотиновые композиции и способы их получения и применения
JP2011519932A5 (cg-RX-API-DMAC7.html)
JP2010505850A5 (cg-RX-API-DMAC7.html)
JP2012517987A5 (ja) 吸入用の医薬組成物のfpd特性を設定する方法
WO2009112273A3 (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
JP2011105739A5 (cg-RX-API-DMAC7.html)
JP2015509788A5 (cg-RX-API-DMAC7.html)
FI3258919T4 (fi) Nasaalinen jauheformulaatio hypoglykemian hoitoon
HK1203149A1 (en) Novel dosage form and formulation of abediterol
UA101652C2 (uk) Композиція для інгаляції, що містить аклідиній для лікування астми та хронічного обструктивного захворювання легень
RU2018113272A (ru) Никотиновые составы и способы их получения и применения
JP2018527386A5 (cg-RX-API-DMAC7.html)
JP2016516751A5 (cg-RX-API-DMAC7.html)
EP3108882A3 (en) Nanoparticle drug delivery
CN116744939A (zh) At-527半硫酸盐的有利形态
JP2021503483A5 (cg-RX-API-DMAC7.html)
JP2022527054A5 (cg-RX-API-DMAC7.html)
MX2020010977A (es) Procedimientos de tratamiento de infecciones fúngicas.
WO2017013542A1 (en) Product based on iron bis-glycinate chelate and alginic acid and/or water-soluble salts thereof, formulations thereof, and pharmaceutical uses thereof
TW202233167A (zh) 血管疾病治療用組成物、血管疾病預防用組成物、高血壓治療用組成物,及高血壓預防用組成物
EP2821062A1 (en) Novel dry powder inhaler formulations
JP2015512923A5 (cg-RX-API-DMAC7.html)